相关实验视频

Updated: May 10, 2026

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

为功能分析和抑制剂选使用异形特异性hSULT1E1化基质进行合理工程

Xiaoting Niu¹, Yufan Fan¹, Guanghao Zhu¹

¹Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

Biosensors & bioelectronics

|February 11, 2025

概括

研究人员为人类雌激素硫转移酶 (hSULT1E1) 设计了一种新型原基质HN-375. 这种工具可以对癌症中的酶活性进行敏感检测,并促进对hSULT1E1抑制剂的高通量查.

科学领域:

生物化学和分子生物学
酶工程是什么? 酶工程是什么?
药物发现药物发现药物发现

背景情况:

人类雌激素硫转移酶 (hSULT1E1) 对于雌激素稳定和代谢异物化合物至关重要.
开发专门用于研究hSULT1E1活动的工具对于了解它在健康和疾病中的作用至关重要.

研究的目的:

为hSULT1E1.1.合理设计和合成高特异性的原基质.
为测量hSULT1E1活性和查抑制剂建立一种敏感的测定方法.

主要方法:

基于结构的虚拟选确定了4-基-1,8-纳胺为支架.
代的结构修改导致了HN-375的开发,HN-375是一种选择性和反应性的基质.
基于光的测试用于活性检测和抑制剂查.

主要成果:

合成了HN-375并证明对hSULT1E1.1.具有很高的特异性和敏感性.
基板在硫化时产生了明亮的绿色光信号 (510 nm),形成HN-375 4-O-硫酸盐.
HN-375能够在肝细胞癌样本和活体器官中感知hSULT1E1活性,并促进了两种强效抑制剂的识别.

结论:

开发了一种突破性的策略,用于为结合酶设计特定的原基质.
HN-375是一种用于在生物环境中检测hSULT1E1活动的实用工具.
开发的试验支持对hSULT1E1抑制剂进行高通量选,以寻找潜在的治疗应用.

关键词:

酶活性分析酶活性分析高通量选的高通量选人类雌激素硫转移酶 (hSULT1E1) 是一种基于结构的基板设计.

更多相关视频

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

相关概念视频

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...